Clinical Trial Update: The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing whether omalizumab reduces the late-phase nasal response to allergen challenge in individuals with cat allergy; the study is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cat Allergy

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Johns Hopkins University | Conditions: Cat Allergy | Phase 2 | Status: COMPLETED | Results posted: 2014-04-07